Sanofi registered sales of $129 million for the drug, up 91% from the previous year. See important safety & full prescribing information. Cemiplimab, marketed as libtayo, was initially developed through a strategic collaboration between regeneron pharmaceuticals, inc Sanofi (nasdaq:sny) has agreed to sell regeneron (nasdaq Regn) exclusive international rights of libtayo (cemiplimab) for $900 million Sanofi will also receive an 11% royalty on global sales of the drug
Sanofi could also receive $100 million if the drug hits regulatory milestones in the next two years. Regeneron will pay partner sanofi $900 million to gain global rights to the companies' cancer immunotherapy libtayo, announcing thursday a deal executives said would position the biotech to become a global oncology leader. under the deal's terms, regeneron will owe sanofi up to $200 million in. Review important safety info & full prescribing information including med guide.
OPEN
